Suppr超能文献

人女性膀胱中肌细胞和非肌细胞β肾上腺素能受体亚型的表达。

β-Adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder.

机构信息

Women's Health New Business Development, Procter & Gamble Pharmaceuticals now Warner Chilcott Pharmaceuticals Inc., Mason, OH, USA.

出版信息

Cell Tissue Res. 2010 Nov;342(2):295-306. doi: 10.1007/s00441-010-1053-x. Epub 2010 Oct 16.

Abstract

β(3)-Adrenergic receptor agonists are currently under clinical development for the treatment of overactive bladder, a condition that is prevalent in postmenopausal women. These agents purportedly relax bladder smooth muscle through a direct action at the myocyte β(3)-receptor. The aim of this study was to examine the expression of the individual beta-adrenergic receptors in full thickness sections from ageing human female bladder. We obtained a series of rabbit polyclonal antibodies generated against each of the three β-adrenergic receptors, and validated their receptor specificity in CHOK1 cells expressing each of the individual receptors. Immunostaining for β(1), β(2), and β(3) were each more prominent in the urothelium than in the detrusor, with all receptors expressed in the same cell types, indicating co-expression of all three receptors throughout the urothelium in addition to the detrusor. Staining of all receptors was also observed in suburothelial myofibroblast-like cells, intramural ganglion cells, and in Schwann cells of intramural nerves. The β(3)-receptor in the human urothelium appears to be functional, as two different selective β(3)-receptor agonists, TAK677 and BRL37344, stimulate cAMP formation in URO tsa cells. Densitometry analysis indicates a persistent expression of all receptors throughout the bladder with increasing age, with the exception of the β(2)-receptor in the urothelium of the trigone, which appears to decrease slightly in older women. These data indicate that β(3)-receptor expression is maintained with age, but may function in concert with other β-receptors. Activation of the myocyte receptor may be influenced by action on non-myocyte structures including the intramural ganglion cells and myofibroblasts.

摘要

β(3)-肾上腺素能受体激动剂目前正在临床开发用于治疗膀胱过度活动症,这是绝经后妇女中常见的病症。这些药物据称通过直接作用于肌细胞β(3)-受体来放松膀胱平滑肌。本研究旨在检查衰老女性膀胱全层切片中各个β-肾上腺素能受体的表达。我们获得了一系列针对每个β-肾上腺素能受体的兔多克隆抗体,并在表达各个受体的 CHOK1 细胞中验证了它们的受体特异性。β(1)、β(2)和β(3)的免疫染色在尿路上皮中比在逼尿肌中更为明显,所有受体均在相同的细胞类型中表达,表明除逼尿肌外,所有三种受体均在整个尿路上皮中共同表达。所有受体的染色也在 suburothelial 肌纤维母细胞样细胞、壁内神经节细胞和壁内神经的施万细胞中观察到。人尿路上皮中的β(3)-受体似乎是功能性的,因为两种不同的选择性β(3)-受体激动剂,TAK677 和 BRL37344,刺激 URO tsa 细胞中环磷酸腺苷的形成。密度分析表明,除三角区尿路上皮的β(2)-受体外,所有受体在整个膀胱中随年龄增长持续表达,而三角区尿路上皮的β(2)-受体似乎在老年女性中略有减少。这些数据表明,β(3)-受体的表达随着年龄的增长而保持,但可能与其他β-受体协同作用。肌细胞受体的激活可能受到包括壁内神经节细胞和肌纤维母细胞在内的非肌细胞结构的作用的影响。

相似文献

9

引用本文的文献

1
Inside the Biology of the β3-Adrenoceptor.β3-肾上腺素能受体的生物学特性
Biomolecules. 2024 Jan 29;14(2):159. doi: 10.3390/biom14020159.
6
Mirabegron in the Management of Overactive Bladder Syndrome.米拉贝隆用于膀胱过度活动症的治疗
Int J Womens Health. 2022 Sep 16;14:1337-1350. doi: 10.2147/IJWH.S372597. eCollection 2022.

本文引用的文献

5
The beta3-adrenoceptor as a therapeutic target: current perspectives.β3肾上腺素能受体作为治疗靶点:当前观点
Pharmacol Res. 2009 Apr;59(4):221-34. doi: 10.1016/j.phrs.2009.01.002. Epub 2009 Jan 24.
8
How reliable are G-protein-coupled receptor antibodies?G蛋白偶联受体抗体的可靠性如何?
Naunyn Schmiedebergs Arch Pharmacol. 2009 Apr;379(4):385-8. doi: 10.1007/s00210-009-0395-y. Epub 2009 Jan 27.
9
Lack of specificity of antibodies directed against human beta-adrenergic receptors.针对人β-肾上腺素能受体的抗体缺乏特异性。
Naunyn Schmiedebergs Arch Pharmacol. 2009 Apr;379(4):403-7. doi: 10.1007/s00210-009-0392-1. Epub 2009 Jan 22.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验